Shao Lee Lin
Founder chez ACELYRIN, INC.
Fortune : 23 M $ au 31/03/2024
Profil
Shao Lee Lin is the founder and CEO of ACELYRIN, Inc. founded in 2020.
Currently, Dr. Lin holds two director positions at Surrozen Operating, Inc. and Surrozen, Inc. respectively.
Dr. Lin has held several director and VP positions at Principia Biopharma, Inc., Third Harmonic Bio, Inc., Gilead Sciences, Inc., AbbVie, Inc., and Horizon Therapeutics Plc.
Dr. Lin was also a trustee at Lake Forest College from 2018 to 2020.
Dr. Lin received an undergraduate degree from Rice University and a doctorate from The Johns Hopkins University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ACELYRIN, INC.
3,55% | 01/04/2024 | 3 452 329 ( 3,55% ) | 23 M $ | 31/03/2024 |
THIRD HARMONIC BIO, INC.
-.--% | 26/10/2022 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Shao Lee Lin
| Sociétés | Poste | Début |
|---|---|---|
| ACELYRIN, INC. | Founder | 27/07/2020 |
| SURROZEN, INC. | Director/Board Member | 01/01/2021 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 02/02/2021 |
Anciens postes connus de Shao Lee Lin
| Sociétés | Poste | Fin |
|---|---|---|
| THIRD HARMONIC BIO, INC. | Director/Board Member | 17/01/2023 |
| PRINCIPIA BIOPHARMA INC. | Director/Board Member | 28/09/2020 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 23/01/2020 |
| Lake Forest College | Director/Board Member | 01/01/2020 |
| ABBVIE INC. | Corporate Officer/Principal | 01/12/2017 |
Formation de Shao Lee Lin
| Rice University | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| THIRD HARMONIC BIO, INC. | Health Technology |
| ACELYRIN, INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
